124 related articles for article (PubMed ID: 28658966)
1. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.
Shiraishi H; Fujiwara Y; Kakuya T; Tsuta K; Motoi N; Miura N; Watabe Y; Watanabe SI; Noro R; Nagashima K; Huang W; Yamada T; Asamura H; Ohe Y; Honda K
Biomark Med; 2017 Sep; 11(9):721-731. PubMed ID: 28658966
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
3. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
Noro R; Honda K; Nagashima K; Motoi N; Kunugi S; Matsubayashi J; Takeuchi S; Shiraishi H; Okano T; Kashiro A; Meng X; Yoshida Y; Watanabe S; Usuda J; Inoue T; Wilber H; Ikeda N; Seike M; Gemma A; Kubota K
Cancer Sci; 2022 Mar; 113(3):1002-1009. PubMed ID: 34845792
[TBL] [Abstract][Full Text] [Related]
4. TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma.
Kuchitsu Y; Nagashio R; Igawa S; Kusuhara S; Tsuchiya B; Ichinoe M; Satoh Y; Naoki K; Murakumo Y; Saegusa M; Sato Y
Biomed Res; 2020; 41(1):53-65. PubMed ID: 32092740
[TBL] [Abstract][Full Text] [Related]
5. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
Noro R; Honda K; Tsuta K; Ishii G; Maeshima AM; Miura N; Furuta K; Shibata T; Tsuda H; Ochiai A; Sakuma T; Nishijima N; Gemma A; Asamura H; Nagai K; Yamada T
Ann Oncol; 2013 Oct; 24(10):2594-2600. PubMed ID: 23899839
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma.
Sereno M; He Z; Smith CR; Baena J; Das M; Hastings RK; Rake G; Fennell DA; Nakas A; Moore DA; Le Quesne J
Histopathology; 2021 May; 78(6):838-848. PubMed ID: 33155719
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
[TBL] [Abstract][Full Text] [Related]
8. Serum carbohydrate antigen 12-5 level enhances the prognostic value in primary adenosquamous carcinoma of the lung: a two-institutional experience.
Lian S; Huang Y; Yang H; Zhao H
Interact Cardiovasc Thorac Surg; 2016 Apr; 22(4):419-24. PubMed ID: 27002010
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
[TBL] [Abstract][Full Text] [Related]
10. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
[TBL] [Abstract][Full Text] [Related]
12. Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma.
Kimura K; Tanaka Y; Tauchi S; Kitamura Y; Nishio W; Sakai Y; Hayashi Y; Yoshimura M; Maniwa Y
Thorac Cancer; 2019 Dec; 10(12):2300-2307. PubMed ID: 31637868
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis.
Zhao K; Yang L; Liu L; Wang G; Zhang J; Gao X; Guo C; Huang C; Chen Y; Li S
BMC Surg; 2024 May; 24(1):140. PubMed ID: 38720305
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
16. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
17. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma.
Saito H; Yamashita M; Ogasawara M; Yamada N; Niisato M; Tomoyasu M; Deguchi H; Tanita T; Ishida K; Sugai T; Yamauchi K
Hum Pathol; 2016 Apr; 50():1-10. PubMed ID: 26997432
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
19. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.
Sasada S; Miyata Y; Mimae T; Tsutani Y; Mimura T; Okada M
Clin Lung Cancer; 2016 Sep; 17(5):433-440.e1. PubMed ID: 26725850
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.
Sarkaria IS; Iyoda A; Roh MS; Sica G; Kuk D; Sima CS; Pietanza MC; Park BJ; Travis WD; Rusch VW
Ann Thorac Surg; 2011 Oct; 92(4):1180-6; discussion 1186-7. PubMed ID: 21867986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
